GSK plc 6-K, filed Jul 6, 2022
GSK plc (GSK)
6-K
2022-07-06
For: 2022-07-06
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on July 6, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 6 July 2022, London UK
Result of General Meeting
GSK plc (LSE/NYSE: GSK) is pleased to announce that at a General
Meeting held at 2.30 pm on Wednesday 6 July 2022 both resolutions
set out in the Notice of General Meeting (included in the Circular
to shareholders published on 1 June 2022) were duly passed by
shareholders.
It is therefore expected that the proposed demerger of Haleon plc
('Haleon') will be completed and that Haleon shares will be
admitted to trading on the London Stock Exchange's Main Market for
listed securities at 8.00 am (UK time) on Monday 18 July 2022. The
GSK Share Consolidation is expected to become effective after 8.00
pm (UK time) on Monday 18 July 2022.
Further information on key dates in relation to the proposed
demerger of Haleon and the GSK Share Consolidation is set out at
the end of this announcement ('Expected Timetable of Principal
Events') and can also be found in the Circular to Shareholders
published on 1 June 2022. The Circular is available on GSK's
website at www.gsk.com/demerger.
The table below provides the results of the poll.
|
Resolution
|
Total votes for(1)(2)
|
%
|
Total votes against(2)
|
%
|
Total votes cast
|
Votes withheld(3)
|
|
|
1
|
Demerger Resolution
|
3,568,610,751
|
99.81
|
6,794,940
|
0.19
|
3,575,405,691
|
7,388,793
|
|
2
|
Related Party Transactions Resolution
|
3,565,834,534
|
99.77
|
8,056,152
|
0.23
|
3,573,890,686
|
8,857,644
|
Shareholders were able to join the General Meeting virtually via
Lumi, Zoom and in person. The full text of the two resolutions
tabled at the General Meeting is contained in the Notice of General
Meeting on pages 157 to 159 of the Circular to Shareholders
published on 1 June 2022.
All valid proxy votes (whether submitted electronically or in hard
copy form) were included in the poll taken at the
meeting.
The above poll results will shortly be available on GSK's website
at www.gsk.com.
In accordance with Listing Rule 9.6.2 of the UK Listing Rules, a
copy of the resolutions will be submitted to the Financial Conduct
Authority and will in due course be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
V A Whyte
Company Secretary
6 July 2022
Notes:
Dr Vishal Sikka's appointment as a Non-Executive Director will
become effective on 18 July 2022. His appointment was announced
on 4
May 2022.
The following table provides further relevant information on the
General Meeting:
|
|
|
|
Issued share capital (excluding Treasury Shares)
|
5,084,180,157
|
|
Total votes cast and votes withheld lodged as a % of GSK's issued
share capital (excluding Treasury Shares)
|
70.47%
|
|
Total shareholder population
|
86,359
|
|
Total number of proxies lodged
|
8,820
|
|
% of shareholders who lodged proxies
|
10.21%
|
|
Number of shareholders, corporate representatives and proxies who
attended the General Meeting:
in
person
virtually
|
46
99
|
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Madeleine Breckon
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
|
|
Analyst/Investor enquiries:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
Disclaimer
GSK makes no representation or warranty as to the appropriateness,
accuracy, completeness or reliability of the information in this
announcement.
This announcement is for information purposes only and is not
intended to and does not constitute or form part of any offer or
invitation to purchase, otherwise acquire, subscribe for, sell,
otherwise dispose of or issue, or any solicitation of any offer to
sell, otherwise dispose of, issue, purchase, otherwise acquire or
subscribe for, any security.
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in GSK's Annual
Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and any
impacts of the COVID-19 pandemic.
All outlooks, ambitions and considerations for Haleon should be
read together with the section "Assumptions and cautionary
statement and regarding forward-looking statements" on page 163 of
the 'Haleon Capital Markets Day all presentation slides' dated 28
February 2022.
Expected Timetable of
Principal Events
The
times and dates set out in the timetable below and throughout this
announcement are indicative only and based on GSK's current
expectations and may be subject to change without further
notice.
Note on trading
Unless
the counterparties specifically agree otherwise, a buyer of GSK's
shares ahead of the ex-dividend date (Monday 18 July 2022) will
assume the benefit of Haleon shares, and the seller would need to
pass the benefit to the buyer, even if the seller is the recorded
owner at the Shareholder Record Time (6.00pm on Friday 15 July
2022).
|
Event
|
Time and date(4)
|
|
Closing of the GSK ADS issuance and cancellation
books (5)
|
8 a.m. New York City time on Thursday 14 July 2022
|
|
Latest time and date for transfers of GSK Shares for the transferee
to be registered on the GSK Share Register at the Shareholder
Record Time
|
6 p.m. on Friday 15 July 2022
|
|
Shareholder Record Time for determining the entitlement to the
Demerger Dividend
|
6 p.m. on Friday 15 July 2022
|
|
ADS Holder Record Time for determining the entitlement to the
Demerger Dividend
|
5 p.m. New York City time on Friday 15 July 2022
|
|
Demerger Dividend to Qualifying Shareholders
|
After 6 p.m. on Friday 15 July 2022
|
|
Completion of Share Exchanges
|
Sunday 17 July 2022
|
|
Commencement of dealings in Existing GSK Shares (ex entitlement to
Haleon Shares) on the LSE
|
8 a.m. on Monday 18 July 2022
|
|
Admission and commencement of dealings in Haleon Shares on the
LSE
|
8 a.m. on Monday 18 July 2022
|
|
CREST accounts credited in respect of Haleon Shares in
uncertificated form
|
As soon as practicable after 8 a.m. on Monday 18 July
2022
|
|
GSK Share Consolidation record time--
|
8.p.m. on Monday 18 July 2022
|
|
GSK Share Consolidation becomes effective
|
After 8 p.m. on Monday 18 July 2022
|
|
GSK Admission and commencement of dealings in New GSK Shares on the
LSE
|
8 a.m. on Tuesday 19 July 2022
|
|
CREST accounts credited in respect of New GSK Shares in
uncertificated form
|
As soon as practicable after 8 a.m. on Tuesday 19 July
2022
|
|
Admission and commencement of dealings in:
Haleon ADSs on the
NYSE
|
9.30 a.m. New York City time on Friday 22 July 2022
|
|
new GSK ADSs on the
NYSE
|
9.30 a.m. New York City time on Friday 22 July 2022
|
|
Opening of the GSK ADS issuance and cancellation
books (5)
|
8 a.m. New York City time on Monday 25 July 2022
|
|
Latest date for despatch of:
definitive share certificates
(where applicable) for New GSK Shares in certificated form to
Qualifying Shareholders on the GSK Share
Register
|
By Monday 1 August 2022
|
|
definitive share certificates
(where applicable) for Haleon Shares in certificated form to
Qualifying Shareholders on the GSK Share
Register(6)
|
By Monday 1 August 2022
|
|
CSN statements for GSK
CSN(7)
|
By Monday 1 August 2022
|
|
opening statements for Haleon
CSN(6)
(7)
|
By Monday 1 August 2022
|
|
Posting of payment advice, CREST accounts credited or payment by
electronic payment in respect of fractional entitlements arising
from the GSK Share Consolidation
|
Week commencing Monday 1 August 2022
|
Notes
to Expected Timetable of Principal Events
(1) The
"for" votes include those giving the Chair discretion. In line with
the notification issued to American Depositary Receipt (ADR)
holders, GSK did not instruct its ADR Depositary to vote any
unvoted ADRs in respect of the General Meeting
resolutions.
(2) Votes
"for" and "against" are expressed as a percentage of the total
votes cast.
(3)
A vote withheld is not a vote in law and is not counted in the
calculation of the proportion of votes "for" or "against" a
resolution.
(4)
Unless otherwise indicated,
all references to time in this timetable are to UK
time.
(5)
The Depositary will suspend the issuance and cancellation of GSK
ADSs from Thursday 14 July 2022 until Monday 25 July 2022. This
means that during this time, you will not be able to convert your
GSK ADSs into GSK Shares, surrender your GSK ADSs and receive
underlying GSK Shares, or deposit your GSK Shares and receive GSK
ADSs.
However, the
closing of the issuance and cancellation books does not impact
trading, and you may continue to trade your GSK ADSs during this
period.
(6)
Subject to the timing of the Haleon Capital
Reduction.
(7)
For CSN Shareholders who have a Shareview Portfolio account, and
have not elected for paper statements to be issued to them, the CSN
statements will only be made available electronically via their
account.
Registered
in England & Wales:
No.
3888792
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
06, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|